Showing results (201-210 of 12,921) with videos related to
Sort By:
Pageof 1,293
Circulation|March 16, 2006
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trialMichelle O'Donoghue, David A Morrow, Marc S Sabatine, et al.Journal of the American Heart Association|February 25, 2016
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 TrialHaiyan Xu, Christian T Ruff, Robert P Giugliano, et al.Circulation. Cardiovascular Quality and Outcomes|November 5, 2020
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 TrialKatherine Vilain, Haiyan Li, Wingham J Kwong, et al.European Heart Journal|August 21, 2001
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-IIR P Giugliano, J Llevadot, R G Wilcox, et al.American Heart Journal|September 21, 2015
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trialBram J Geller, Robert P Giugliano, Eugene Braunwald, et al.Journal of the American College of Cardiology|May 24, 2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysisElliott M Antman, Stephen D Wiviott, Sabina A Murphy, et al.Current Opinion in Hematology|November 14, 1997
High-dose chemotherapy with autologous stem cell support for breast cancerL Vahdat, K AntmanThe Review of Economics and Statistics|September 17, 2016
INCENTIVES TO IDENTIFY: RACIAL IDENTITY IN THE AGE OF AFFIRMATIVE ACTIONFrancisca Antman, Brian DuncanJournal of Thrombosis and Thrombolysis|October 6, 2007
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16Benjamin A Olenchock, Stephen D Wiviott, Sabina A Murphy, et al.Pageof 1,293